Insider Sale: Director at $THC Sells 836 Shares

Richard W Fisher, a director at $THC, sold 836 shares on 06-05-2025 for approximately $144,761, representing about 6.9% of their holdings in that class of stock. Over the past six months, $THC insiders have executed 19 sales and no purchases, with several executives, including James L Bierman, Paola M Arbour, and J Robert Kerrey, contributing significantly to the selling activity. Institutional investors displayed mixed sentiment in Q1 2025, with PACER ADVISORS reducing their stake by 100% while CITADEL ADVISORS and AMERIPRISE FINANCIAL increased their positions substantially; analysts currently have a generally positive outlook on $THC, with four buy ratings and a median price target of $162.5.

Analysis

Recent trading activity for $THC reveals a consistent pattern of insider selling, with director Richard W Fisher selling 836 shares for approximately $144,761 on June 5, 2025, reducing his stake by 6.9%. Over the past six months, $THC insiders have executed 19 sales and no purchases, totaling significant divestments by executives including James L Bierman (20,000 shares for ~$3.25M), Paola M Arbour (14,199 shares for ~$2.37M), and J Robert Kerrey (15,748 shares for ~$2.14M). Institutional sentiment in Q1 2025 was mixed: 293 institutions added shares while 369 decreased positions. Notably, PACER ADVISORS, INC. liquidated its entire holding of 3,832,530 shares (valued at ~$515.5M), and QUBE RESEARCH & TECHNOLOGIES LTD reduced its position by 1,165,529 shares (-82.7%). Conversely, CITADEL ADVISORS LLC significantly increased its stake by 1,615,412 shares (+643.2%), AMERIPRISE FINANCIAL INC added 1,524,642 shares (+348.4%), and BOSTON PARTNERS grew its holdings by 1,016,010 shares (+692.9%). FMR LLC also increased its position by 1,295,346 shares (+17.9%), while BLACKROCK, INC. reduced its holdings by 1,056,210 shares (-10.0%). Wall Street analysts maintain a positive outlook, with four firms issuing buy or overweight ratings in recent months (Wells Fargo, Bank of America Securities, Morgan Stanley, KeyBanc) and no sell ratings. The median price target from two analysts over the last six months is $162.5, with KeyBanc setting a target of $185.0 and Goldman Sachs at $140.0. The recent insider sale by Fisher occurred at an approximate price of $173.16 per share.

Key Decisions for Investors

• Investors should carefully weigh the persistent and unanimous insider selling activity against the currently positive Wall Street analyst ratings and the significant, albeit mixed, institutional investment flows.
• The substantial divestment by PACER ADVISORS and notable reductions by QUBE RESEARCH & TECHNOLOGIES and BLACKROCK warrant scrutiny, even as other large institutions like CITADEL ADVISORS and AMERIPRISE FINANCIAL have significantly increased their positions, indicating a divergence of institutional opinion on $THC's valuation or prospects.
• Consider that the median analyst price target of $162.5 is below the recent insider sale price of approximately $173.16, which could suggest that insiders may perceive the stock as adequately or fully valued at current levels, despite bullish analyst sentiment.